All News
Don’t be ‘ticked’: TYK2 is not a JAK!
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
Read Article
Exciting Data for SLE: Plenaries from #ACR22
ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!
Read Article
Anifrolumab shows long-term promise in patients with lupus
EurekAlert!
Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.
Read Article
Industry Abstract Previews of ACR 2022
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list.
Read Article
AS, Lupus and Subclinical RA: What I'm looking forward to at ACR22
As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.
Read Article
Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs
Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds
@RheumNow https://t.co/a0tNFn5Wqr
Eric Dein ericdeinmd ( View Tweet)
Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Janet Pope Janetbirdope ( View Tweet)
Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
13 studies included: 70% with low risk of bias
BEL improved clinical response at W52 vs non-users OR 1.44
Decrease risk of severe cutaneous flare OR 0.51
Most studies against placebo group
@RheumNow https://t.co/2bSwNKRHZZ
Eric Dein ericdeinmd ( View Tweet)
#ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #lupus is not normal and is IFN-riched. Also implication for future therapy development to target organ/tissues vs circulation @RheumNow https://t.co/rSnLYrZoMO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH
7.3% had "severe non-adherence" by HCQ levels
Hazard ratio of flare 3.3, damage 4.26, and death 5.4
Not surprising, but very useful for pt discussion
Checking HCQ levels are helpful!
@Rheumnow https://t.co/S7P9oTPRGJ
Eric Dein ericdeinmd ( View Tweet)
Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @rheumnow #ACR22. https://t.co/5GrtMYYZSv
TheDaoIndex KDAO2011 ( View Tweet)
#ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cell–targeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon!
I'm actually skeptical of this in SLE; are B cells really the answer?
w/better targeting & dx selection, this could be game changing
#ACR22 https://t.co/Z6t99ZIeMy
Mike Putman EBRheum ( View Tweet)
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Robert B Chao, MD doctorRBC ( View Tweet)
#acr22 The Rise of JAK in rheumatology
Look for Ab1117 in plenary 2 tomorrow for DEU and SLE
@RheumNow https://t.co/nLpXGyrhfJ
Eric Dein ericdeinmd ( View Tweet)
#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
